Skip to main content
BioCentury on BioBusiness
Feature Story

Pain politics

FDA's Hamburg defends Zohydro approval, integrity of science-based regulation

By Steve Usdin
Washington Editor

FDA's approval of Zohydro ER hydrocodone bitartrate from Zogenix Inc. has reignited debates about the best ways to balance the needs of pain patients and concerns about opioid drug addiction, abuse and overdoses. Calls from powerful politicians to reverse FDA's decision to approve Zohydro have also revived concerns about the politicization of drug oversight.

The voices of pain patients have been drowned out by Zohydro's critics, in part because critics of FDA's approval have made extraordinary claims about the drug's potency and abuse potential.

Full Article

    ASCO's honest broker

    ASCO is developing an initiative to facilitate off-label access to targeted cancer therapies. If successful, the system could serve as a model for third-party bodies that could manage early access to experimental therapies.


    CAR hits pothole

    Adverse events led to protocol revisions in Sloan Kettering's trial of CD19-targeted CAR T cells. But partner Juno Therapeutics and other CAR players don't think this indicates a class effect.


    Minoryx: Mediating rare metabolism

    Minoryx both identifies novel chaperones and repurposes drugs to treat inherited metabolic diseases.

  • True North: Dynamiting complement

    True North's TNT009 inhibits an upstream target in the classical complement pathway that could lead to greater efficacy and an improved safety profile relative to other complement inhibitors.


    Pain politics

    FDA Commissioner Margaret Hamburg responds to critics of the agency's decision to approve Zogenix's Zohydro and warns about consequences for the integrity of science-based regulation.


    Ebb & Flow

    Double-dippers defer follow-on plans. Snake eyes for Cytos. Kaleo's royalty deal. Epirus makes it move. Steve Harr's jump to Juno. Also: ALK-Abello; Medivir; ThromboGenics; Topotarget; Zogenix, et al.

FDA Pain


    Contaminating cancer genomes

    Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the enzyme and are looking to partner with industry.


    Translational tidbits

    AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.

  • Expanding into new (bromo)domains

    The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.


    Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases tumor formation and relapse in mice, but more druggable targets upstream of it might be better suited for further development.


    This Week in Therapeutics

    Inhibiting IL-17A or IL-23 to alleviate periodontitis; antagonizing KCNA3 to treat asthma; activating CD31 signaling to counter autoimmune and inflammatory conditions; and more...


    This Week in Techniques

    Isoacyl dipeptides to increase insulin yield from chemical synthesis; binary nylon-3 copolymers containing cationic and hydrophobic subunits for antimicrobial activity; markers of distinct SHH-driven medulloblastomas; and more...

Subscribe Now
Free Trial